As global financial landscapes shift, Noah outlines a new AI-first approach to helping families protect and grow their wealth.
Updated
January 8, 2026 6:31 PM
Noah’s Black Diamond Summit. PHOTO: ARK WEALTH
Noah Holdings, one of Asia’s leading wealth management firms serving global Chinese high-net-worth families, hosted its annual Black Diamond Summit in Macau from December 7–11. The city has become a significant gathering place for Noah’s community, where clients, partners, and experts converge each year to explore how global trends are transforming wealth and family life. This year’s theme, “AI Together, Co-Generating the Future”, set the tone for a conversation about how modern wealth management must adapt in an age defined by artificial intelligence.
More than 3,000 attendees joined discussions that connected technology, global mobility, and long-term family planning. The Summit built on earlier sessions held in Shanghai, creating a continuous dialogue around one central question: how can families prepare for a world that is becoming more digital, more complex and more interconnected?
A major moment came when Noah introduced “Noya”, its new AI Relationship Manager. Noya is now part of the upgraded iARK Hong Kong and Singapore apps. It is built to support licensed human advisors, not replace them. The goal is simple: combine human judgment with AI intelligence to help clients understand their wealth more clearly and manage it across borders. Noya offers real-time insights, deeper personalisation, cleaner access to global financial information, smoother coordination between regions, and end-to-end execution through Noah’s global booking centres.
The Summit’s tone shifted toward long-term thinking when Co-Founder and Chairwoman Norah Wang delivered her keynote, “From Chaos to Clarity: Building a Global Operating System for Wealth Management”. She reflected on twenty years of serving more than 400,000 clients and explained that families today face new pressures. As she put it, “The real pain point for Chinese families today is not investment performance, but navigating the growing complexities of a global lifestyle”. Her message was straightforward: wealth is no longer just about returns. It is about managing uncertainty in a world where technology, geopolitics, and mobility collide.
Wang described how two major shifts have shaped modern wealth—first the Internet Era, which changed how people built wealth, and now what she calls the AI Civilisation Era, which is changing how people must protect it. She outlined the forces that influence today’s decisions: geopolitical shifts, persistent inflation, the rising importance of security and supply-chain technologies, the spread of AI, and the need for stronger family governance across generations. Each of these factors adds complexity, and families need tools that help them see the bigger picture.
To respond to this reality, Noah presented its integrated global wealth infrastructure. It is built on three pillars:
Together, these pillars function as an AI-supported system designed to simplify global complexity and help families preserve long-term stability.
One of the most discussed conversations featured Noah’s CEO, Zander Yin, and Tony Shale, Co-Founder & Chairman of Asian Private Banker China. They spoke about how AI is transforming private banking in Asia. Their view was that wealth management is moving from a product-centred model to one led by insight, trust, and human-tech collaboration. AI may accelerate analysis, but human expertise will continue to guide judgment, relationships, and long-term strategy.
The closing message of the Summit centred on redefining what prosperity means in an AI-driven age. For Noah, wealth is no longer a destination. It is an ongoing journey through a world that is increasingly fast-moving and unpredictable. As Wang noted, “With AI reshaping the very foundations of civilisation, wealth and financial freedom represent not a static endpoint, but a continuous journey. Here, we find our purpose: to help global Chinese investors navigate an increasingly complex world and achieve true prosperity, supported by resilient wealth management infrastructure and deep human expertise”.
The Summit ended on that note—a reminder that the future of wealth is not only about financial assets, but about clarity, confidence and the ability to adapt as the world transforms.
Keep Reading
How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.